Previous 10 | Next 10 |
FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with Knee Osteoarthritis RMAT Designation Enables Closer FDA Interactions to Support Accelerated Approval CANTON, Mass., Jan. 11, ...
CANTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, toda...
Today, we do a deep dive on Organogenesis Holdings. It has an interesting and growing niche in the market, has strong analyst support and recently addressed its funding needs. A full investment analysis and recommendation follows in the paragraphs below. For further details ...
Insider activity is getting increasingly informative to follow up during this tough market environment. Insider activity declined significantly in November, indicating that they believe the market is overvalued. However, one can still find very interesting stocks by following sign...
Organogenesis Holdings ([[ORGO]] +6.6%) director Ades Alan A. acquired 486K shares at $3.25/share; also acquired 347,153 shares at $3.25/share from indirect beneficial ownership (Robert Harry Erani Frick Trust).Post the transactions, the director owned $68.8M worth of shares.Press R...
Organogenesis is a revenue-generating regenerative medicines company with a long pipeline. The company has decades of operating history behind it. Despite some concerns discussed below, the company looks highly interesting. For further details see: Organogenesis: Revenue...
Are Analysts Right About These Penny Stocks? When you think of penny stocks , what comes to mind first? Is it companies with well-established track records and 10% annual dividends? Most traders and investors alike usually think about these as early-stage companies involving higher ...
Organogenesis (ORGO) prices its public offering of 17.5M Class A common shares at $3.25 per share. Underwriters' over-allotment is an additional ~2.6M shares. Closing date is November 17.Gross proceeds should be ~$56.9M.Yesterday's close was $3.67.Shares down 2% premarket on light v...
Organogenesis (ORGO) has priced its previously announced public offering of 17.5M Class A shares at $3.25 per share, with gross proceeds of $56.9M.Offer price represents ~11% discount from last close price of $3.67MUnderwriters have an option to purchase up to 2.6M additional shares. The offe...
Organogenesis Holdings (ORGO) is offering to sell 17.5M Class A shares in a public offering. Price and other terms are not yet determined.Underwriters' over-allotment is an additional 2.625M shares.Morgan Stanley and SVB Leerink are acting as joint book-running managers.Recently, ORGO also an...
News, Short Squeeze, Breakout and More Instantly...
Organogenesis Holdings Inc. Company Name:
ORGO Stock Symbol:
NASDAQ Market:
Organogenesis Holdings Inc. Website:
CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, to...
2024-06-28 10:00:07 ET Brooks O'Neil from Lake Street issued a price target of $5.00 for ORGO on 2024-06-28 08:01:00. The adjusted price target was set to $5.00. At the time of the announcement, ORGO was trading at $2.64. ORGO currently trades -43.21% versus its 52 week ...
CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today an...